Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.
An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and…
Adding abemaciclib to fulvestrant improved PFS in patients with HR+, HER2- advanced breast cancer whose disease progressed on prior treatment with a CDK4/6 inhibitor.
Sarcomas are a broad group of cancers that originate from connective tissues, such as the blood or lymph vessels, gastrointestinal tract, fat tissue, tendons, smooth…
In all MIBC patients who received an avelumab regimen as neoadjuvant therapy, achieving a pCR was associated with longer OS.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
MD Anderson’s Cancerwise podcast will feature insights from our experts on cancer diagnosis and treatment, research breakthroughs, and prevention, as well as stories from survivors…
Stephen V. Liu, MD, details the phase 1/2 ARROS-1 study evaluating the selective ROS1 inhibitor zidesamtinib in patients with ROS1 fusion–positive non–small cell lung cancer.
Beginning in 2012, The ASCO Post introduced Narratives in Oncology, a special commemorative issue profiling several of the many leaders in the oncology community.
The FDA’s Medical Devices Advisory Committee recommends the approval of the Shield blood test for CRC screening in adults at average risk for CRC.